To date in the Phase 1/2 portion of the trial, six late-stage participants have been treated with OPGx-LCA5, and all six have experienced clinically meaningful improvements in vision, providing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback